NCT04297020
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Other
Key Eligibility Criteria:
Gender: Female
Age: 35 Years to 65 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must be undergoing endocrine therapy
Exclusions:
https://ClinicalTrials.gov/show/NCT04297020